A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Lapatinib (Primary)
- Indications Adenoid-cystic-carcinoma; Salivary gland cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Aug 2005 New trial record.